Kainomyx will lead the technical strategy for drug discovery and clinical phases, Aurigene will focus on developing scalable drug chemistry and Dr. Reddy’s will advise on the regulatory and market access processes.
The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities and an R&D center in Zagreb, Croatia.
